Evidence map›Paper›PMID 35404759›Full record

ArticleCell cycle (Georgetown, Tex.)2022

Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway.

Tianjiao Lai, Haifeng Qiu, Lulu Si, Yu Zhen, Danxia Chu, Ruixia Guo

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Advances in MiRNAs Involved in Endometrial Carcinoma.Combinatorial chemistry & high throughput screening · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Tianjiao LaiDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.ORCID 0000-0002-7191-4753
Haifeng QiuDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
Lulu SiDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
Yu ZhenDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
Danxia ChuDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
Ruixia GuoDepartment of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou Henan, China.
First Affiliated Hospital of Zhengzhou University · CNZhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endometrial carcinoma (EC) originates from the endometrium and is one of the most common tumors in female patients, and its incidence has continued to increase in recent decades. LncRNAs are involved in the pathogenesis and metastasis of a variety of malignant tumors, which indicates that lncRNAs can be used as tumor diagnostic markers and potential therapeutic targets. In this study, we analyzed the RNA transcripts of EC cells from The Cancer Genome Atlas (TCGA) and first reported a novel lncRNA, BMPR1B-AS1, that was more highly expressed in endometrial cancer tissues than in adjacent tissues, and BMPR1B-AS1 could promote endometrial cancer cell proliferation and metastasis. Bioinformatics prediction and experimental results both suggested that BMPR1B-AS1 could modulate the malignant behaviors of endometrial cancer cell lines by sponging miR-7-2-3p to modulate DCLK1, and a DCLK1 inhibitor blocked the activation of the PI3K/Akt/NF-κB signaling pathway. Collectively, this study suggests that the BMPR1B-AS1/miR-7-2-3p/DCLK1 axis contributes to the proliferation and metastasis of endometrial cancer cells via the PI3K/Akt/NF-κB pathway.

Indexed as

Endometrial NeoplasmsMicroRNAsRNA, Long NoncodingBiomarkers, TumorBone Morphogenetic Protein Receptors, Type ICell Line, TumorCell MovementCell ProliferationDoublecortin-Like KinasesFemaleGene Expression Regulation, NeoplasticHumansNF-kappa BPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktBiomarkers, TumorBMPR1B protein, humanBone Morphogenetic Protein Receptors, Type IDCLK1 protein, humanDoublecortin-Like KinasesMicroRNAsMIRN7-1 microRNA, humanNF-kappa BPhosphatidylinositol 3-KinasesProtein Serine-Threonine KinasesProto-Oncogene Proteins c-aktRNA, Long NoncodingceRNAEndometrial cancerlncRNA BMPR1B-AS1metastasisproliferation

Identifiers

PMID35404759
PMCPMC9291686
OpenAlexW4223432140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.